Wednesday, July 8, 2026

Patent intelligence · US

US 9975867

Synthetic process for preparing 2-furoic acid derivatives

granted A61PA61P3/06A61P35/00A61P43/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 308
Patent details — US 9975867
Jurisdiction
US
Status
granted
Grant date
May 22, 2018
Expiration
May 17, 2038
Applicant
Dermira, Inc.
Claims
15
CPC classes
A61P, A61P3/06, A61P35/00, A61P43/00
View on Google Patents ↗

Quick answer

US 9975867 (Synthetic process for preparing 2-furoic acid derivatives) is held by Dermira, Inc.. Status: granted. Granted May 22, 2018. Expires May 17, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Dermira, Inc.
Grant date
Expiration
Claims
15
CPC classes
A61P, A61P3/06, A61P35/00, A61P43/00

More from Dermira, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 9975867?

US 9975867 (Synthetic process for preparing 2-furoic acid derivatives) is held by Dermira, Inc.. Status: granted. Granted May 22, 2018. Expires May 17, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9975867?

Dermira, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 9975867 expire?

Our index shows an expiration date of May 17, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.